JP2023514452A - 生体模倣ウイルスペプチドの特定及びその使用 - Google Patents

生体模倣ウイルスペプチドの特定及びその使用 Download PDF

Info

Publication number
JP2023514452A
JP2023514452A JP2022550908A JP2022550908A JP2023514452A JP 2023514452 A JP2023514452 A JP 2023514452A JP 2022550908 A JP2022550908 A JP 2022550908A JP 2022550908 A JP2022550908 A JP 2022550908A JP 2023514452 A JP2023514452 A JP 2023514452A
Authority
JP
Japan
Prior art keywords
scaffold
binding
cov
amino acid
ace2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022550908A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514452A5 (https=
JPWO2021173879A5 (https=
Inventor
ワトソン、アンドレ・ロナルド
イズボルスキー、アレクサンドル
Original Assignee
リガンダル・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リガンダル・インコーポレイテッド filed Critical リガンダル・インコーポレイテッド
Publication of JP2023514452A publication Critical patent/JP2023514452A/ja
Publication of JP2023514452A5 publication Critical patent/JP2023514452A5/ja
Publication of JPWO2021173879A5 publication Critical patent/JPWO2021173879A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
JP2022550908A 2020-02-25 2021-02-25 生体模倣ウイルスペプチドの特定及びその使用 Withdrawn JP2023514452A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062981453P 2020-02-25 2020-02-25
US62/981,453 2020-02-25
US202063002249P 2020-03-30 2020-03-30
US63/002,249 2020-03-30
US202062706225P 2020-08-05 2020-08-05
US62/706,225 2020-08-05
US202063091291P 2020-10-13 2020-10-13
US63/091,291 2020-10-13
PCT/US2021/019739 WO2021173879A1 (en) 2020-02-25 2021-02-25 Identification of biomimetic viral peptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2023514452A true JP2023514452A (ja) 2023-04-05
JP2023514452A5 JP2023514452A5 (https=) 2024-03-05
JPWO2021173879A5 JPWO2021173879A5 (https=) 2024-03-05

Family

ID=77492020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550908A Withdrawn JP2023514452A (ja) 2020-02-25 2021-02-25 生体模倣ウイルスペプチドの特定及びその使用

Country Status (9)

Country Link
US (1) US20230242592A1 (https=)
EP (1) EP4110366A4 (https=)
JP (1) JP2023514452A (https=)
KR (1) KR20220158723A (https=)
CN (1) CN115461068A (https=)
AU (1) AU2021227918A1 (https=)
CA (1) CA3172878A1 (https=)
IL (1) IL295863A (https=)
WO (1) WO2021173879A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
US20230218742A1 (en) * 2020-05-22 2023-07-13 Riken Multiple antigenic peptide against coronavirus and immunostimulating composition containing the same
CA3181026A1 (en) 2020-06-03 2021-12-09 Samit GANGULY Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
IL310012A (en) 2021-07-14 2024-03-01 Regeneron Pharma Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
WO2023044494A2 (en) 2021-09-17 2023-03-23 Kotlyar David Oral vaccine via dental bacteria and emitted peptides to prevent covid-19 infection
IT202200025416A1 (it) * 2022-12-13 2024-06-13 Univ Pisa Biosensore per la rilevazione di particelle virali
CN117153245B (zh) * 2023-10-18 2024-03-19 无锡市疾病预防控制中心 预测新型冠状病毒S蛋白RBD区域与hACE2受体相互作用的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017046801A1 (en) * 2015-09-17 2017-03-23 Ramot At Tel-Aviv University Ltd. Coronaviruses epitope-based vaccines
CN110582301A (zh) * 2016-12-14 2019-12-17 利甘达尔股份有限公司 用于核酸和蛋白质有效负载递送的方法和组合物
US11365239B2 (en) * 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof

Also Published As

Publication number Publication date
EP4110366A1 (en) 2023-01-04
CA3172878A1 (en) 2021-09-02
EP4110366A4 (en) 2024-03-27
AU2021227918A1 (en) 2022-10-20
IL295863A (en) 2022-10-01
US20230242592A1 (en) 2023-08-03
KR20220158723A (ko) 2022-12-01
WO2021173879A1 (en) 2021-09-02
CN115461068A (zh) 2022-12-09

Similar Documents

Publication Publication Date Title
JP2023514452A (ja) 生体模倣ウイルスペプチドの特定及びその使用
Tortorici et al. Structural basis for human coronavirus attachment to sialic acid receptors
Mittal et al. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2
Nguyen et al. Does SARS-CoV-2 bind to human ACE2 more strongly than does SARS-CoV?
WO2021188576A1 (en) Modified angiotensin-converting enzyme 2 (ace2) and use thereof
Requena et al. Identification of novel candidate epitopes on SARS-CoV-2 proteins for South America: A review of HLA frequencies by country
Freedman et al. Computational prediction of the heterodimeric and higher-order structure of gpE1/gpE2 envelope glycoproteins encoded by hepatitis C virus
Freitas et al. Shedding light on the inhibitory mechanisms of SARS-CoV-1/CoV-2 spike proteins by ACE2-designed peptides
Nuqui et al. Simulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens
Delgado et al. Extracellular loops of the Treponema pallidum FadL orthologs TP0856 and TP0858 elicit IgG antibodies and IgG+-specific B-cells in the rabbit model of experimental syphilis
Havranek et al. A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo
Watson et al. Peptide antidotes to SARS-CoV-2 (COVID-19)
Huang et al. Putative receptor binding domain of bat-derived coronavirus HKU9 spike protein: evolution of betacoronavirus receptor binding motifs
Dutta et al. All-atom simulations of human ACE2-spike protein RBD complexes for SARS-CoV-2 and some of its variants: Nature of interactions and free energy diagrams for dissociation of the protein complexes
Panchal et al. Peptide‐based inhibitors for SARS‐CoV‐2 and SARS‐CoV
Nguyen et al. Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation
Kibria et al. A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus
Das et al. Epitope-based potential vaccine candidate for humoral and cell-mediated immunity to combat severe acute respiratory syndrome coronavirus 2 pandemic
De Cae et al. Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base
Isaacs et al. A nanobody-based therapeutic targeting Nipah virus limits viral escape
Haußner et al. Peptide Paratope Mimics of the Broadly Neutralizing HIV‐1 Antibody b12
Sokullu et al. Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase
Marzinek et al. A funneled conformational landscape governs flavivirus fusion peptide interaction with lipid membranes
Tan et al. Identification of putative, stable binding regions through flexibility analysis of HIV‐1 gp120
Wang et al. Structure-guided design of a prefusion GPC trimer induces neutralizing responses against LASV

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240226

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20250324